Unique ID issued by UMIN | UMIN000007010 |
---|---|
Receipt number | R000008272 |
Scientific Title | Randomized controlled trials for the efficacy between famotidine alone and combination of famotidine and egualen sodium hydrate on gastric ulcer healing for following eradication therapy for Helicobactor pylori |
Date of disclosure of the study information | 2012/01/04 |
Last modified on | 2019/07/12 15:41:19 |
Randomized controlled trials for the efficacy between famotidine alone and combination of famotidine and egualen sodium hydrate on gastric ulcer healing for following eradication therapy for Helicobactor pylori
The effect of egualen sodium hydrate on gastric ulcer healing for following eradication therapy for Helicobactor pylori
Randomized controlled trials for the efficacy between famotidine alone and combination of famotidine and egualen sodium hydrate on gastric ulcer healing for following eradication therapy for Helicobactor pylori
The effect of egualen sodium hydrate on gastric ulcer healing for following eradication therapy for Helicobactor pylori
Japan |
Gastric ulcer for following eradication therapy for Helicobactor pylori
Gastroenterology |
Others
NO
To evaluate the effect of combination of famotidine and egualen sodium hydrate on gastric ulcer healing for following eradication therapy for Helicobactor pylori
Efficacy
The healing rate of gastric ulcer within 8 weeks
The healing rate of gastric ulcer after 8 weeks
QOL score (GSRS) after 2 weeks and 8 weeks
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Famotidine 20mg twice per day
8 weeks
Famotidine20mg twice per day +Egualens sodium hydrate15mg twice per day
8 weeks
20 | years-old | <= |
Not applicable |
Male and Female
1.Helicobactor pylori infected patients diagnosed with peptic ulcer by endoscopic examinations
2.Patients with active gastric ulcer(A1/A2)
3.Patients whose diameter of ulcer is 1.5cm or longer
4.Patients of 20 year or older
5.Patients who can understand the consents of this trial is obtained in written form.
1.Patients with drug allegy
2.Patient taking Atananavir sulfate,Pimozide and Ergatamine-containing drugs
3.Patient who has been mononucleosis
4.Patients with severe liver and renal dysfunction, and serious heart-lung complication.
5.Pregnant, females who suckles, or females who wish to become pregnant
6.Patients who have eradication therapy of Helicobactor pylori infection
7.Patient who take PPI or H2RA within 1 month before obtaining informed consent
8.Patients who take mucosal protective medicine within 2 weeks before obtaining informed consent
9.Others,patients who are judged to be inadequate to participate in this trial by the investigator
100
1st name | |
Middle name | |
Last name | Tetsuya Mine M.D PhD |
Tokai University,School of Medicine
Division of Gastroenterology and Hepatology department of internal medicine
143 shimokasuya,Isehara City,Kanagawa 259-1193
1st name | |
Middle name | |
Last name |
Tokai University School of Medicine
Division of Gastroenterology and Hepatology department of internal medicine
0463-93-1121
Tokai University School of Medicine
None
Self funding
NO
2012 | Year | 01 | Month | 04 | Day |
Unpublished
Completed
2010 | Year | 07 | Month | 05 | Day |
2010 | Year | 07 | Month | 05 | Day |
2010 | Year | 10 | Month | 01 | Day |
2010 | Year | 10 | Month | 01 | Day |
2012 | Year | 01 | Month | 04 | Day |
2019 | Year | 07 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008272
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |